Melatonin (HIGH-DOSE — antioxidant / oncology / neuroprotection use)

→ See melatonin.md for low-dose phase-shift / sleep-onset use (0.3-0.5 mg evening dose for DSWPD chronotype migration — Dylan's STRONG-CANDIDATE V5 indication). This file covers the fundamentally different pharmacological use case at 20-300 mg, where melatonin functions as a direct/indirect antioxidant and mitochondrial protectant rather than as a circadian signal.

Two pharmacology regimes — not the same drug at different doses

Sleep / phase-shift regime (0.3-3 mg, covered in melatonin.md): signaling. Hits MT1 (acute sleep promotion) and MT2 (SCN phase shift) at GPCR-saturating concentrations within physiological plasma range. Half-life 30-50 min IR. Cleared before morning. This is the regime virtually all consumer melatonin use occupies.

Antioxidant / oncology regime (20-300 mg, this file): biochemistry. Plasma levels reach 1,000-100,000× the endogenous nighttime peak. MT1/MT2 are saturated/desensitized within minutes; the receptor-mediated effects are clinically irrelevant past the first hour. What matters is the direct redox chemistry, the mitochondrial accumulation, and the transcriptional upregulation of the endogenous antioxidant network.

The same molecule, dosed two orders of magnitude higher, pivots from a hormone to a free-radical scavenger / mitochondrial drug. This is the central point Dylan needs to internalize: this file is not "more melatonin for sleep" — it is a different intervention that happens to use the same compound.

Direct radical scavenging — the Reiter cascade

Russel Reiter (UT San Antonio) has spent ~40 years characterizing melatonin's redox chemistry. The key insight: melatonin is one of the few endogenous molecules whose oxidation products are themselves potent antioxidants. A single melatonin molecule, in a typical reactive-oxygen environment, can neutralize ~4 ROS via a sequential cascade:

1. Melatonin + •OH (hydroxyl radical) → cyclic 3-hydroxymelatonin (c3OHM). First scavenging event.
2. c3OHM + ROS → AFMK (N1-acetyl-N2-formyl-5-methoxykynuramine). Second scavenging event; AFMK is itself a radical scavenger.
3. AFMK + ROS → AMK (N1-acetyl-5-methoxykynuramine). Third event.
4. AMK + ROS → further oxidation products. Fourth event.

Compare to most direct antioxidants (vitamin C, vitamin E, glutathione) which neutralize one radical per molecule before requiring regeneration. Melatonin's cascade is roughly 4× more "stoichiometrically efficient" per molecule — and unlike vitamin C / E, melatonin is small, amphipathic, and crosses every major biological membrane: plasma membrane, BBB, mitochondrial double membrane, blood-retinal barrier, placenta, gonad-blood barrier. It is one of very few antioxidants that gets inside the mitochondrial matrix at meaningful concentration.

Mitochondrial accumulation — ~100× plasma

Multiple studies (Acuña-Castroviejo, Reiter, Tan) have demonstrated that mitochondria actively concentrate melatonin to ~100× plasma levels. The mechanism is partly oligopeptide transporter-mediated (PEPT1/PEPT2) and partly local mitochondrial synthesis (some literature suggests mitochondria themselves can synthesize small amounts of melatonin from tryptophan in situ, though this is debated).

The functional consequence: at 50-100 mg oral dose, mitochondrial melatonin concentration reaches the high-µM range — well above the IC50 for inhibition of mitochondrial permeability transition pore (mPTP) opening, well above the threshold for direct scavenging of mitochondrial-membrane peroxyl radicals, and well above receptor-binding constants. Melatonin in this dose range:

• Stabilizes the mitochondrial inner membrane against lipid peroxidation
• Preserves complex I and complex IV electron transport chain activity under oxidative stress
• Inhibits mPTP opening — a key step in apoptotic cell death triggered by ischemia-reperfusion injury, sepsis, TBI
• Maintains mitochondrial membrane potential (Δψm) during stress
• Reduces cytochrome-c release — preventing downstream caspase activation

This is the mechanism behind the ICU/sepsis trials, the neonatal HIE trials, and the entire TBI/stroke animal literature. Mitochondrial preservation is the unifying mechanism for high-dose melatonin's protective effects across very different clinical contexts.

Indirect antioxidant — transcriptional upregulation

Beyond direct scavenging, high-dose melatonin upregulates the endogenous antioxidant defense network via:

• NRF2 pathway activation — induces transcription of glutathione peroxidase (GPx), superoxide dismutase (SOD1, SOD2), catalase, glutathione-S-transferase, NQO1, heme oxygenase-1 (HO-1). NRF2 activation is the same pathway hit by sulforaphane, curcumin, and exercise — but melatonin's NRF2 activation is dose-dependent and reaches meaningful magnitudes at the 20-100 mg range.
• SIRT1 upregulation — deacetylates FOXO transcription factors, shifting cellular metabolism toward stress resistance + mitochondrial biogenesis. Overlaps with the longevity-NAD+ pathway.
• NF-κB suppression — reduces transcription of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α). Important for ICU/sepsis context and theoretically for chronic neuroinflammation post-TBI.
• Upregulation of glutathione synthesis via increased γ-glutamylcysteine synthetase activity. Layered with NAC's cysteine-supply mechanism.

So: direct radical scavenging at the molecule's site of presence + mitochondrial preservation + transcriptional amplification of the body's own antioxidant machinery. Three-way mechanism. The clinical question is whether this translates to meaningful endpoints in healthy young populations at chronic dose, or whether the mechanism only matters in pathological oxidative-stress contexts (cancer, sepsis, TBI, ischemia, neonatal hypoxia).

MT3 (NQO2) — minor relevance

The historical "MT3 receptor" was reclassified as quinone reductase 2 (NQO2), an enzymatic detoxification protein that binds melatonin at high concentrations. Activation of NQO2 contributes to phase-2 detoxification of quinones and reactive metabolites. At high oral doses this is a real (if minor) contributor to the antioxidant phenotype.

Why this is NOT redundant with vitamin C / E / NAC / curcumin

The natural question: Dylan already has NAC (1,200 mg/day), vitamin C (500 mg/day), curcumin (500 mg/day), DHA omega-3 (2 g/day), and is adding astaxanthin (12 mg/day) and apigenin (50 mg/day) to V5. Why add high-dose melatonin?

The case for non-redundancy:

• Compartmentalization. Most antioxidants are spatially limited. Vitamin C is aqueous-phase. Vitamin E is membrane-lipid-phase. NAC contributes upstream cysteine for glutathione synthesis but is not itself a strong direct scavenger. Curcumin is amphipathic but BBB penetration is modest. Astaxanthin spans the bilayer but doesn't accumulate in mitochondria specifically. Melatonin is the only one that concentrates in mitochondria at ~100× plasma — the place where the most damaging ROS (superoxide → hydroxyl via Fenton) are generated. This is the single strongest non-redundancy argument.
• Cascade scavenging stoichiometry. ~4 ROS per molecule via the AFMK/AMK pathway. Most direct scavengers are 1:1.
• Indirect (NRF2/SIRT1) amplification. Melatonin's transcriptional reach is broader than NAC's. Curcumin and sulforaphane overlap on NRF2 specifically.
• Anti-mPTP / cytochrome-c-stabilizing effects — these are not replicated by the V4/V5 antioxidant lineup.

The case against:

• Most of the unique mitochondrial benefit is documented in pathological-oxidative-stress contexts (sepsis, TBI, ischemia). Whether a 20yo MMA athlete with subconcussive impact load reaches the threshold of pathological mitochondrial stress where this matters is unproven.
• Astaxanthin already does mitochondrial-membrane stabilization at meaningful magnitude.
• Diminishing returns on antioxidant stacking are real — there is a "U-shaped" curve in some literature where excessive antioxidant load impairs hormesis-driven adaptive responses (the same critique applied to high-dose vitamin E in athletes).

Net mechanistic verdict: non-redundant in mitochondrial-oxidative-stress contexts; potentially redundant for routine baseline antioxidant load. Argues for intermittent / PRN use post-impact rather than chronic daily.